MMV Project Director: Pierre Hugo
Although the WHO Guidelines for the Treatment of Malaria include the use of rectal artesunate for pre-referral treatment for severe malaria, there is currently no WHO prequalified or stringent regulatory authority approved product of appropriate strength and presentation. This has hampered widespread availability and use of rectal artesunate, in programmes funded by international donors.
The project team is developing an rectal artesunate product that will be submitted to WHO Medicines Prequalification Programme in 2015. Read more information about this project in our Access areas of work.